A Phase I/II, Open Label, Multicenter, Pilot Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacodynamics of FFP104 in Subjects Previously Diagnosed With Primary Biliary Cirrhosis (PBC)
Phase of Trial: Phase I/II
Latest Information Update: 18 Oct 2017
At a glance
- Drugs FFP 104 (Primary)
- Indications Biliary cirrhosis
- Focus Adverse reactions
- Sponsors FF Pharma
- 10 Jun 2017 Biomarkers information updated
- 29 Sep 2016 This study has been discontinued in Netherlands as per European Clinical Trials Database record.
- 23 Aug 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.